| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Urolithins are gut microbiota–derived dibenzopyran-6-one metabolites formed from ellagitannins → ellagic acid. They are the bioactive, systemically relevant forms responsible for most of the anticancer, mitochondrial, and signaling effects attributed to pomegranate and berry consumption. Ellagic acid itself is largely confined to the gut lumen; urolithins are what reach circulation and tissues. Urolithin A (UA), Most studied; mitophagy, anticancer, anti-inflammatory Humans fall into urolithin metabotypes: Metabotype Description Approx. Population A Produces UA (best profile) ~40% B Produces UB ± UA ~25–30% 0 Non-producer ~30% ROS Modulation (Context-Dependent) Cancer cells: -Mild ROS ↑ or redox stress → apoptosis, growth arrest Normal cells: -ROS ↓, improved mitochondrial efficiency This duality is why urolithins are less chemo-antagonistic than classic antioxidants. Anticancer Signaling ↓ PI3K/AKT/mTOR ↓ Wnt/β-catenin ↓ NF-κB, STAT3 Cell-cycle arrest (G1/S) Unlike sulforaphane or NAC, urolithins: -Do not strongly upregulate NRF2 in cancer cells -May normalize NRF2 signaling in normal cellsDirect Urolithin A Supplements: Bypass microbiome dependency Urolithin A–type activity — Cancer vs Normal Cell Effects
|
| Source: |
| Type: |
| Cartilage is a flexible connective tissue found in multiple areas of the body, including joints, the ear and nose, and intervertebral discs. The most common type of arthritis, osteoarthritis involves wear-and-tear damage to a joint's cartilage. Chondrosarcoma is a rare type of bone cancer that develops in cartilage cells. Cartilage Degradation: Cancer can lead to the degradation of cartilage, particularly in joint-related cancers. This degradation can result in pain and loss of function, impacting the patient's quality of life. Biomarkers: Specific proteins and genes associated with cartilage metabolism (e.g., collagen types, aggrecan, and matrix metalloproteinases) can serve as biomarkers for cancer diagnosis and prognosis. Their expression levels may indicate the presence of malignancy or the aggressiveness of a tumor. |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4875- | Uro, | Impact of the Natural Compound Urolithin A on Health, Disease, and Aging |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | ostP, | NA | - | Review, | IBD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:383 Target#:539 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid